📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial (2015)

First Author: McInnes I

Attributed to: Infrastructure for collaboration: Leeds MRC Medical Bioinformatics Centre funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(15)61134-5

PubMed Identifier: 26135703

Publication URI: http://europepmc.org/abstract/MED/26135703

Type: Journal Article/Review

Parent Publication: The Lancet

Issue: 9999

ISSN: 0140-6736